NO329981B1 - Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. - Google Patents

Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. Download PDF

Info

Publication number: NO329981B1
Authority: NO; Norway
Prior art keywords: use according; combination; drug; treatment; combination therapy
Prior art date: 2000-11-06

Application number

NO20032027A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032027L (no

NO20032027D0 (no

Inventor

Steve Weitman

Naoto Takahashi

Maurizio D'incalci

Glynn Thomas Faicloth

Rafaella Giavazzi

Andreas Gescher

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-06

Filing date

2003-05-06

Publication date

2011-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27399908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329981(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-06 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2003-05-06 Publication of NO20032027D0 publication Critical patent/NO20032027D0/no

2003-07-04 Publication of NO20032027L publication Critical patent/NO20032027L/no

2011-01-31 Publication of NO329981B1 publication Critical patent/NO329981B1/no

Links

PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title claims description 170
229960000977 trabectedin Drugs 0.000 title claims description 166
XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 title claims description 162
239000003814 drug Substances 0.000 title claims description 44
239000002246 antineoplastic agent Substances 0.000 title claims description 15
229940041181 antineoplastic drug Drugs 0.000 title claims description 12
239000011885 synergistic combination Substances 0.000 title claims description 6
238000004519 manufacturing process Methods 0.000 title description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 87
229960004679 doxorubicin Drugs 0.000 claims description 44
229940079593 drug Drugs 0.000 claims description 42
206010028980 Neoplasm Diseases 0.000 claims description 29
229930012538 Paclitaxel Natural products 0.000 claims description 27
229960001592 paclitaxel Drugs 0.000 claims description 27
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 27
238000011282 treatment Methods 0.000 claims description 24
FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 21
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 21
206010039491 Sarcoma Diseases 0.000 claims description 20
229960004316 cisplatin Drugs 0.000 claims description 20
238000002648 combination therapy Methods 0.000 claims description 11
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 11
229960005277 gemcitabine Drugs 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 9
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 9
229960001099 trimetrexate Drugs 0.000 claims description 9
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
229960003048 vinblastine Drugs 0.000 claims description 6
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 6
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
229960003957 dexamethasone Drugs 0.000 claims description 5
206010006187 Breast cancer Diseases 0.000 claims description 3
208000026310 Breast neoplasm Diseases 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 2
201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
238000005538 encapsulation Methods 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
239000002077 nanosphere Substances 0.000 claims description 2
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
206010038389 Renal cancer Diseases 0.000 claims 1
201000010982 kidney cancer Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
210000004027 cell Anatomy 0.000 description 61
230000000694 effects Effects 0.000 description 26
230000002195 synergetic effect Effects 0.000 description 19
FTICVONBLRGQJW-UHFFFAOYSA-N 3-BrB-PP1 Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)N=C1CC1=CC=CC(Br)=C1 FTICVONBLRGQJW-UHFFFAOYSA-N 0.000 description 17
230000000996 additive effect Effects 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
230000022534 cell killing Effects 0.000 description 12
210000004881 tumor cell Anatomy 0.000 description 11
230000001472 cytotoxic effect Effects 0.000 description 10
ZNJRHEVYOYMEHR-UHFFFAOYSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;trihydrochloride Chemical compound Cl.Cl.Cl.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZNJRHEVYOYMEHR-UHFFFAOYSA-N 0.000 description 9
208000021712 Soft tissue sarcoma Diseases 0.000 description 9
239000000654 additive Substances 0.000 description 9
231100000433 cytotoxic Toxicity 0.000 description 9
201000009410 rhabdomyosarcoma Diseases 0.000 description 9
241000700159 Rattus Species 0.000 description 8
230000000259 anti-tumor effect Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
201000008968 osteosarcoma Diseases 0.000 description 8
201000008808 Fibrosarcoma Diseases 0.000 description 7
102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 7
101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
238000000034 method Methods 0.000 description 7
206010033128 Ovarian cancer Diseases 0.000 description 6
230000008485 antagonism Effects 0.000 description 6
210000000481 breast Anatomy 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000008406 drug-drug interaction Effects 0.000 description 5
238000001802 infusion Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
206010019851 Hepatotoxicity Diseases 0.000 description 4
239000012829 chemotherapy agent Substances 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
231100000304 hepatotoxicity Toxicity 0.000 description 4
230000007686 hepatotoxicity Effects 0.000 description 4
229960003552 other antineoplastic agent in atc Drugs 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000005243 Chondrosarcoma Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000008050 Total Bilirubin Reagent Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012510 hollow fiber Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
238000011255 standard chemotherapy Methods 0.000 description 3
231100000338 sulforhodamine B assay Toxicity 0.000 description 3
238000003210 sulforhodamine B staining Methods 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010008635 Cholestasis Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
210000000013 bile duct Anatomy 0.000 description 2
206010006007 bone sarcoma Diseases 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
231100000359 cholestasis Toxicity 0.000 description 2
230000007870 cholestasis Effects 0.000 description 2
238000011278 co-treatment Methods 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000890 drug combination Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000007866 hepatic necrosis Effects 0.000 description 2
206010019692 hepatic necrosis Diseases 0.000 description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000033607 mismatch repair Effects 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
101100468589 Arabidopsis thaliana RH30 gene Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
101150066553 MDR1 gene Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
241000251555 Tunicata Species 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000008439 repair process Effects 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
210000001944 turbinate Anatomy 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Compounds Of Unknown Constitution (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

NO20032027A 2000-11-06 2003-05-06 Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel. NO329981B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US24623300P	2000-11-06	2000-11-06
US24809500P	2000-11-13	2000-11-13
US34598201P	2001-10-19	2001-10-19
PCT/GB2001/004902 WO2002036135A2 (en)	2000-11-06	2001-11-06	Compositions for antitumour treatment containing ecteinascidin 743

Publications (3)

Publication Number	Publication Date
NO20032027D0 NO20032027D0 (no)	2003-05-06
NO20032027L NO20032027L (no)	2003-07-04
NO329981B1 true NO329981B1 (no)	2011-01-31

Family

ID=27399908

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032027A NO329981B1 (no)	2000-11-06	2003-05-06	Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel.

Country Status (25)

Country	Link
US (3)	US20040108086A1 (da)
EP (1)	EP1365808B1 (da)
JP (2)	JP4391083B2 (da)
KR (1)	KR100718946B1 (da)
CN (1)	CN100374162C (da)
AT (1)	ATE495793T1 (da)
AU (2)	AU2002212499B2 (da)
BG (1)	BG107843A (da)
BR (1)	BR0115162A (da)
CA (1)	CA2428160C (da)
CY (1)	CY1112361T1 (da)
CZ (1)	CZ20031327A3 (da)
DE (1)	DE60143911D1 (da)
DK (1)	DK1365808T3 (da)
EA (1)	EA005564B1 (da)
HK (1)	HK1060067A1 (da)
HU (1)	HUP0400648A3 (da)
IL (1)	IL155781A0 (da)
MX (1)	MXPA03003975A (da)
NO (1)	NO329981B1 (da)
NZ (1)	NZ525730A (da)
PL (1)	PL361389A1 (da)
PT (1)	PT1365808E (da)
SK (1)	SK287901B6 (da)
WO (1)	WO2002036135A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
CZ20031327A3 (cs) *	2000-11-06	2003-11-12	Pharma Mar, S. A.	Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
IL161430A0 (en) *	2001-10-19	2004-09-27	Pharma Mar Sa	Pharmaceutical compositions containing ecteinascidin 743
GB0202544D0 (en) *	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
JP2007511499A (ja)	2003-11-13	2007-05-10	ファーマ・マール・エス・アー・ウー	コンビネーション
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
CN1897949A (zh) *	2003-11-14	2007-01-17	马尔药品公司	包含使用et－743和紫杉醇来治疗癌症的联合疗法
WO2006005602A2 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) *	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
KR101287918B1 (ko) *	2004-10-26	2013-07-19	오르토 바이오테크 프로덕츠 엘.피.	엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신
DK1658848T3 (da) *	2004-10-29	2007-11-26	Pharma Mar Sa	Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
DE602006020335D1 (de) *	2005-11-25	2011-04-07	Pharma Mar Sa	Verwendung von parp-1-hemmern
AU2008313634A1 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Prognostic molecular markers for ET-743 treatment
ME03501B (me) *	2010-11-12	2020-04-20	Pharma Mar Sa	Kombinovana terapija sa antitumorskim antibiotikom
GB201217439D0 (en) *	2012-09-28	2012-11-14	Topotarget As	Combination therapy
WO2014165818A2 (en)	2013-04-05	2014-10-09	T Cell Therapeutics, Inc.	Compositions and methods for preventing and treating prostate cancer
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
CN109276719A (zh) *	2018-11-01	2019-01-29	中山万汉制药有限公司	含有奥利司他纳米粒与蛋白激酶抑制剂的组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149804A (en) *	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
US5256663A (en) *	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) *	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en) *	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
GB9508195D0 (en) *	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
US5985876A (en) *	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CA2288964A1 (en) *	1997-05-21	1998-11-26	Genentech, Inc.	Novel administration of thrombopoietin
CN1157189C (zh) *	1998-04-06	2004-07-14	伊利诺伊大学评议会	半合成海鞘素
CN100548988C (zh) *	1998-05-11	2009-10-14	法马马有限公司	海鞘素743的代谢物
JP2000081438A (ja) *	1998-06-25	2000-03-21	Sekisui Chem Co Ltd	被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) *	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es) *	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7247892B2 (en) *	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) *	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
AU2001281232A1 (en) *	2000-08-11	2002-02-25	City Of Hope	The anti-neoplastic agent ET-743 inhibits trans activation by SXR
CZ20031327A3 (cs) *	2000-11-06	2003-11-12	Pharma Mar, S. A.	Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
CZ20032266A3 (cs) *	2001-03-06	2004-02-18	Bristol-Myers Squibb Company	Dávkovací formy pro ošetřování nádorů
JP4391038B2 (ja) *	2001-05-10	2009-12-24	パナソニック株式会社	電気炊飯器
IL161430A0 (en) *	2001-10-19	2004-09-27	Pharma Mar Sa	Pharmaceutical compositions containing ecteinascidin 743
US20040019027A1 (en) *	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
JP2007511499A (ja) *	2003-11-13	2007-05-10	ファーマ・マール・エス・アー・ウー	コンビネーション
CN1897949A (zh) *	2003-11-14	2007-01-17	马尔药品公司	包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
WO2006005602A2 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) *	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
KR101287918B1 (ko) *	2004-10-26	2013-07-19	오르토 바이오테크 프로덕츠 엘.피.	엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신
DK1658848T3 (da) *	2004-10-29	2007-11-26	Pharma Mar Sa	Formuleringer omfattende ecteinascidin og et disaccharid
DE602006020335D1 (de) *	2005-11-25	2011-04-07	Pharma Mar Sa	Verwendung von parp-1-hemmern
US20100009906A1 (en) *	2006-05-12	2010-01-14	Pharma Mar, S.A.	Anticancer Treatments

2001
- 2001-11-06 CZ CZ20031327A patent/CZ20031327A3/cs unknown
- 2001-11-06 PL PL01361389A patent/PL361389A1/xx not_active Application Discontinuation
- 2001-11-06 JP JP2002538946A patent/JP4391083B2/ja not_active Expired - Fee Related
- 2001-11-06 PT PT01980710T patent/PT1365808E/pt unknown
- 2001-11-06 CN CNB018218032A patent/CN100374162C/zh not_active Expired - Fee Related
- 2001-11-06 AU AU2002212499A patent/AU2002212499B2/en not_active Ceased
- 2001-11-06 MX MXPA03003975A patent/MXPA03003975A/es active IP Right Grant
- 2001-11-06 US US10/416,086 patent/US20040108086A1/en not_active Abandoned
- 2001-11-06 BR BR0115162-2A patent/BR0115162A/pt not_active IP Right Cessation
- 2001-11-06 NZ NZ525730A patent/NZ525730A/xx not_active IP Right Cessation
- 2001-11-06 IL IL15578101A patent/IL155781A0/xx unknown
- 2001-11-06 AT AT01980710T patent/ATE495793T1/de active
- 2001-11-06 HU HU0400648A patent/HUP0400648A3/hu unknown
- 2001-11-06 DK DK01980710.6T patent/DK1365808T3/da active
- 2001-11-06 CA CA002428160A patent/CA2428160C/en not_active Expired - Fee Related
- 2001-11-06 EA EA200300544A patent/EA005564B1/ru not_active IP Right Cessation
- 2001-11-06 SK SK549-2003A patent/SK287901B6/sk not_active IP Right Cessation
- 2001-11-06 EP EP01980710A patent/EP1365808B1/en not_active Revoked
- 2001-11-06 DE DE60143911T patent/DE60143911D1/de not_active Expired - Lifetime
- 2001-11-06 AU AU1249902A patent/AU1249902A/xx active Pending
- 2001-11-06 KR KR1020037006228A patent/KR100718946B1/ko not_active IP Right Cessation
- 2001-11-06 WO PCT/GB2001/004902 patent/WO2002036135A2/en active IP Right Grant
2003
- 2003-05-06 NO NO20032027A patent/NO329981B1/no not_active IP Right Cessation
- 2003-05-23 BG BG107843A patent/BG107843A/bg unknown
2004
- 2004-05-04 HK HK04103120.3A patent/HK1060067A1/xx not_active IP Right Cessation
2009
- 2009-02-27 JP JP2009046557A patent/JP2009114212A/ja active Pending
- 2009-09-02 US US12/552,347 patent/US20090324744A1/en not_active Abandoned
2011
- 2011-04-18 CY CY20111100397T patent/CY1112361T1/el unknown
- 2011-12-30 US US13/341,262 patent/US20120107417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK5492003A3 (en)	2004-03-02
HUP0400648A3 (en)	2012-09-28
CN100374162C (zh)	2008-03-12
HUP0400648A2 (hu)	2004-06-28
CY1112361T1 (el)	2015-12-09
US20090324744A1 (en)	2009-12-31
PT1365808E (pt)	2011-04-08
PL361389A1 (en)	2004-10-04
DE60143911D1 (de)	2011-03-03
KR20030048127A (ko)	2003-06-18
JP2004517056A (ja)	2004-06-10
EP1365808B1 (en)	2011-01-19
NO20032027L (no)	2003-07-04
EP1365808A2 (en)	2003-12-03
ATE495793T1 (de)	2011-02-15
JP2009114212A (ja)	2009-05-28
KR100718946B1 (ko)	2007-05-16
CZ20031327A3 (cs)	2003-11-12
SK287901B6 (sk)	2012-03-02
CA2428160C (en)	2009-10-13
MXPA03003975A (es)	2004-02-12
WO2002036135A2 (en)	2002-05-10
NZ525730A (en)	2004-12-24
CN1486193A (zh)	2004-03-31
EA005564B1 (ru)	2005-04-28
EA200300544A1 (ru)	2003-08-28
DK1365808T3 (da)	2011-05-16
AU1249902A (en)	2002-05-15
CA2428160A1 (en)	2002-05-10
BR0115162A (pt)	2003-10-21
JP4391083B2 (ja)	2009-12-24
US20040108086A1 (en)	2004-06-10
US20120107417A1 (en)	2012-05-03
IL155781A0 (en)	2003-12-23
AU2002212499B2 (en)	2006-11-02
HK1060067A1 (en)	2004-07-30
WO2002036135A3 (en)	2003-04-10
NO20032027D0 (no)	2003-05-06
BG107843A (bg)	2004-06-30

Legal Events

Date	Code	Title	Description
2015-06-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO329981B1 (no)	2011-01-31	Anvendelse av ET-743 ved fremstilling av et medikament, samt synergistisk kombinasjon som omfatter ET-743 og et annet antitumorlegemiddel.
AU2002212499A1 (en)	2002-07-18	Compositions for antitumour treatment containing ecteinascidin 743
EP2154971B1 (en)	2011-12-28	A synergistic pharmaceutical combination for the treatment of cancer
RU2429838C2 (ru)	2011-09-27	Комбинированная химиотерапия
US8927530B2 (en)	2015-01-06	Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
RU2391101C2 (ru)	2010-06-10	Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
US20110015135A1 (en)	2011-01-20	Antitumoral Treatments
US9119877B2 (en)	2015-09-01	Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent
US20110070232A1 (en)	2011-03-24	Combination Therapy with an Antitumor Alkaloid
MXPA05001430A (es)	2005-06-06	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas.
ES2358787T3 (es)	2011-05-13	Composiciones para tratamiento antitumoral que contienen ecteinascidina 743.
Muggia et al.	1996	iManagement (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer